Clazakizumab is under clinical development by CSL and currently in Phase III for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD). According to GlobalData, Phase III drugs for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Clazakizumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Clazakizumab overview
Clazakizumab (ALD-518, BMS-945429) is under development for the treatment of Coronavirus disease 2019 (COVID-19), end-stage kidney disease in patients undergoing dialysis, kidney transplant patients with late antibody-mediated rejection. It is administered through intravenous and subcutaneous routes. The therapeutic candidate is a monoclonal antibody targeting interleukin-6 (IL-6). It was also under development for the treatment of Crohn's disease, graft versus host disease (GVHD) after allogeneic hematopoietic stem cell transplant (HSCT), cancer, oral mucositis associated with head and neck cancer subjects receiving concomitant chemotherapy and radiotherapy and for the treatment of non-small cell lung cancer-related fatigue, anemia, cancer cachexia, psoriatic arthritis (PsA) and moderate to severe rheumatoid arthritis (RA).
CSL overview
CSL discovers, develops, manufactures, commercializes and distributes biopharmaceuticals and related products. Its portfolio encompasses plasma-derived products for the treatment of hemophilia, hereditary angioedema, von Willebrand disease, inherited primary and secondary immune deficiencies, respiratory disease, neurological disorders and protein-based medicines for treating serious human illnesses. The company also provides products for the prevention of hemolytic disease in newborns, infection in solid organ transplant recipients and to treat specific infections for victims of trauma and burns. CSL markets an array of vaccines, anti-venoms and pharmaceutical products of various other manufacturers. The company sells its products in Australia, Germany, Switzerland, the US, the UK and other countries. CSL is headquartered in Parkville, Victoria, Australia.
For a complete picture of Clazakizumab’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
